Pharnext Announces the Opening of the First U.S. Study Site for its PLEO-CMT International Pivotal Phase 3 Trial in Charcot-Marie-Tooth Disease Type 1A

PARIS, April 25, 2016 -- (Healthcare Sales & Marketing Network) -- Pharnext today announced the opening of the first U.S. trial site for its PLEO-CMT pivotal Phase 3 clinical trial of its lead pleodrug PXT3003 in Charcot-Marie-Tooth Disease Type 1A (CMT1A... BiopharmaceuticalsPharnext, PLEO-CMT, Pleotherapy, Charcot-Marie-Tooth
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news